A new SPECT/CT imaging approach can accurately differentiate between inflammation and fibrosis in interstitial lung disease (ILD) patients. Researchers used the molecular imaging agent ⁹⁹ᵐTc-maraciclatide to visualize inflammation, which is crucial for determining treatment decisions.
PSMA PET scans have been shown to detect bone metastases that conventional imaging misses, resulting in faster disease progression and worse overall survival. Patients with these undetected lesions are at a higher risk of progressing to treatment-resistant cancer and dying sooner.
Researchers developed a novel PET imaging approach to detect immune-related adverse events in patients receiving immunotherapy. The approach uses CCR2-targeted radiotracer to visualize both tumor progression and cardiac inflammatory responses. Co-treatment with itacitinib improved tumor response while reducing cardiac inflammation.
Johnson aims to protect and advance the scope of practice for nuclear medicine technologists, strengthening the national workforce pipeline through education-driven partnerships with industry. She will also formalize standardized training resources as new technologies are introduced.
Shannon Youngblood has been elected as the new president of the SNMMI Technologist Section. She will focus on amplifying visibility through advocacy, building a more inclusive workforce through educational opportunities, and streamlining professional development to stay current with advancements in theranostics and cardiac PET-CT.
Dr. Richard E. Carson has made significant contributions to the understanding and application of nuclear medicine, particularly in neuroscience and neuropsychiatric disorders. His work led to the development of diverse tracer kinetic modeling techniques and innovative imaging systems like NeuroEXPLORER.
Irène Buvat, a pioneering researcher, has received the SNMMI's George Charles de Hevesy Nuclear Pioneer Award for her groundbreaking work in molecular imaging quantification. Her contributions have led to improved diagnosis and treatment of cancer through the development of simulation and radiomics tools.
A new machine-learning model uses pre-therapy PET/CT scans to estimate radiation dose to tumors and healthy organs, improving patient selection and reducing toxicity risk. The study's findings suggest a promising ability to predict post-therapy dosimetry, which may optimize treatment plans for individual patients.
The Society of Nuclear Medicine and Molecular Imaging recognized six new Fellows for their exceptional contributions to the field. The SNMMI Fellowship honors members who have demonstrated excellence in scientific discovery, educational efforts, or clinical practice.
Vasken Dilsizian, MD, has received the Minoshima-Pappas Transformational Leadership Award for his vision and leadership in advancing nuclear medicine and molecular imaging. He has made significant contributions to the field of cardiovascular diseases through his innovative scientific work.
Researchers have made significant breakthroughs in nuclear medicine, with studies revealing uneven radiation doses in tiny kidney structures, improving survival rates for prostate cancer patients through targeted radiation therapy, and developing a new PET imaging approach to detect abdominal cancer spread. These advancements aim to im...
Researchers have developed a targeted radiopharmaceutical treatment that can effectively slow tumor growth in pancreatic ductal adenocarcinoma, achieving complete remission in preclinical models. The treatment targets CD44v6 expression and has shown promise as a new option for patients with this highly aggressive cancer.
Recent studies published in The Journal of Nuclear Medicine investigate the safety of kidney treatments, effectiveness of radioactive iodine for dialysis patients, and the use of new PET imaging agents to detect breast cancer spread. Researchers also explored emerging techniques like FAPI PET scans for improved detection and treatment ...
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
Dr. Chun Li has been awarded the SNMMI Mars Shot Research Fund Award to investigate the PET radiotracer 64Cu-DbCD11b for detecting vulnerable atherosclerotic plaques. The study aims to assess the non-invasive assessment of vulnerable plaques and aid in patient risk identification and treatment.
Researchers Ansel Hillmer and Eric Webb have received the $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award to advance imaging research in infection and inflammation for Alzheimer's disease. They aim to develop a PET radiotracer targeting CSF1R to diagnose and monitor brain inflammation.
Researchers Haj-Mirzaian and Heidari aim to develop non-invasive imaging biomarker <sup> 18 </sup> F-NaF PET/CT for early calciphylaxis diagnosis in dialysis-dependent patients. This could lead to timely interventions, reduced mortality, and improved patient outcomes.
Dr. David H. Ballard, MD, has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop novel PET/MR imaging techniques for metabolic activity and inflammation in Crohn's disease. The study aims to improve biologically informed decision-making and guide treatment decisions.
Dr. Carolyn J. Anderson has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop a PET radiotracer for imaging vaso-occlusive crisis in sickle cell disease. The award will support the production and validation of an easy-to-produce and high-yielding PET radiotracer, 18F-LLP2A, for rapid translation to patients.
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.
Researchers used advanced PET imaging techniques to study the effects of traumatic spinal cord injuries on nerve cells. Additionally, whole-body PET scans were used to map brain-body immune cross-talk during immune responses.
Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
The new framework addresses inefficiencies in current PET system accreditation methods, introducing a contrast recovery coefficient-based system for reproducibility and reliability. Universal adoption will provide advantages for stakeholders, enabling trusted data comparison across the globe.
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
This supplement highlights key areas of focus for theranostics, including clinical lessons, education, science, multidisciplinary collaboration, and equity. It also explores new frontiers beyond oncology and examines finance, sustainability, policy, strategy, and future directions.
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
A first-in-human study found that a single dose of the alpha-emitting radionuclide <sup> 211 </sup> At was both well-tolerated and effective in achieving disease control without molecularly targeted drugs. The therapy has potential to reduce treatment burden and broaden access to effective care for patients with refractory disease.
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.